Key result
New-generation TKIs improved major molecular response at 1 year compared with imatinib (OR 2.22; 95% CI 1.87-2.63) but increased the risk of vascular occlusive events in patients with CML.
Why the study?
Do new-generation BCR-ABL tyrosine kinase inhibitors increase the risk of vascular occlusive events compared to imatinib in patients with chronic myeloid leukemia?
Meta-Analysis (n=3,043)
Do new-generation BCR-ABL tyrosine kinase inhibitors increase the risk of vascular occlusive events compared to imatinib in patients with chronic myeloid leukemia?
Effect estimate: OR 2.22 (95% CI 1.87-2.63)
New-generation TKIs (dasatinib, nilotinib, ponatinib) significantly increase the risk of vascular occlusive events compared to imatinib in patients with CML, without improving 1-year overall survival.
No takes yet. Share an insight, caveat, or question.
Prompts caution selecting new TKIs in CML to limit vascular events; confirms safety trade-offs despite MMR gains.
Douxfils et al. (2016) conducted a meta-analysis in Chronic myeloid leukemia (CML) (n=3,043). New-generation TKIs (dasatinib, nilotinib, ponatinib, bosutinib) vs. Imatinib was evaluated on Major molecular response at 1 year (OR 2.22, 95% CI 1.87-2.63). New-generation TKIs improved major molecular response at 1 year compared with imatinib (OR 2.22; 95% CI 1.87-2.63) but increased the risk of vascular occlusive events in patients with CML.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: